MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
- An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
- MediWoundis a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.
- Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn, wound care and tissue repair.
- MW005, is a topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.